Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13991723 | 0.85 | GRM5 (0.48) | GRM5CYP3A4 | |
| SCHEMBL4661655 | 0.83 | GRM5 (0.43) | GRM5ALDH1A1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL4660532 | 0.83 | GRM5 (0.43) | GRM5ALDH1A1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL4757957 | 0.80 | GRM5 (0.39) | GRM5ALDH1A1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL4663256 | 0.80 | GRM5 (0.45) | GRM5ALDH1A1L3MBTL1KDM4ENOTUM | |
| SCHEMBL5487679 | 0.72 | GRM5 (0.55) | GRM5CYP3A4 | |
| SCHEMBL5485386 | 0.72 | GRM5 (0.55) | GRM5CYP3A4 | |
| SCHEMBL1581685 | 0.70 | GRM5 (0.43) | GRM5CYP3A4NOTUM | |
| SCHEMBL5478827 | 0.70 | GRM5 (0.53) | GRM5ALDH1A1CYP3A4 | |
| SCHEMBL5488717 | 0.70 | GRM5 (0.53) | GRM5ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1919911-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007021574-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | GRM5, GRM1, GRIN1 | GRM5 1/4885ALDH1A1 769/4885L3MBTL1 3673/4885 |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | GRM5, GRM1, GRIN1 | GRM5 1/4885ALDH1A1 769/4885L3MBTL1 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.